Venus Concept Announces First Quarter of Fiscal Year 2024 Financial Results
Venus Concept (NASDAQ: VERO) announced its Q1 2024 financial results, reporting a 15% YoY revenue decline to $17.5 million, but exceeding its forecast by 6%. Operating expenses dropped 11% to $19.4 million, while the net loss was $9.8 million, slightly higher than Q1 2023's $9.7 million. The gross profit fell 15% to $11.6 million with a consistent gross margin of about 66.6%. Notably, cash operations used $2.9 million, a 51% reduction from the previous year. The company secured $5.0 million in debt financing from Madryn Asset Management to enhance near-term liquidity. Strategic milestones include the TGA clearance in Australia for Venus Versa Pro and approval for Venus Bliss MAX in Israel. Venus Concept forecasts Q2 2024 revenue to be at least $16.5 million.
- Exceeded Q1 2024 revenue forecast by 6%, reporting $17.5 million.
- Cash used in operations decreased by 51% YoY to $2.9 million.
- Secured $5.0 million debt financing from Madryn Asset Management.
- Received TGA clearance in Australia for Venus Versa Pro.
- Received approval for Venus Bliss MAX in Israel.
- Operating expenses reduced by 11% to $19.4 million.
- Total revenue decreased by 15% YoY.
- Gross profit decreased by 15% to $11.6 million.
- Net loss increased slightly to $9.8 million from $9.7 million YoY.
- Significant revenue reduction in subscription systems by 39%.
- Total debt obligations increased to $76.7 million from $74.9 million.
Insights
The financial results of Venus Concept for the first quarter of 2024 present a mixed picture for investors. The company reported total revenue of
However, the company's high operating expenses and significant net loss of
The gross margin held steady at
With cash and cash equivalents at
The recent announcements regarding TGA clearance in Australia and Israel's Ministry of Health approval for Venus Concept's products represent significant strides in regulatory achievements. These approvals can potentially open up new markets, driving future revenue growth. The Venus Versa Pro and Venus Bliss MAX have garnered acceptance in prominent regions, which can enhance the company's market penetration and brand credibility.
However, these developments need to be evaluated in the context of the ongoing restructuring efforts and financial health. The decline in international revenue by
Moreover, the subscription model, which represented only
The purchase of Venus Concept's outstanding senior debt by affiliates of Madryn Asset Management and the subsequent Loan and Security Agreement mark significant moves in restructuring the company's financial obligations. Securing
Such debt refinancing can provide a lifeline for Venus Concept amid its turnaround efforts. However, the company's high debt levels, standing at approximately
Investors should closely monitor the company's ability to meet near-term liquidity requirements and progress toward achieving cash flow breakeven. Effective management of debt obligations and generating sufficient cash flow will be critical to Venus Concept's long-term viability.
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2024.
First Quarter 2024 Summary & Recent Progress:
- Company continues to execute against Transformational Plan
- Cash used in operations of
$2.9 million , down51% year-over-year from$5.9 million - Cash system revenue in first quarter 2024 represented approximately
75% of total systems and subscriptions revenue, compared to66% in the prior year period
- Cash used in operations of
- Total revenue of
$17.5 million , down15% year-over-year but exceeded first quarter estimate of at least$16.5 million by6% or$1.0 million . - On April 3, 2024, the Company announced that it received Therapeutic Goods Administration (TGA) clearance in Australia to market the Venus Versa Pro system.
- On April 8, 2024, the Company announced that it received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.
- On April 24, 2024, the Company announced that its existing Main Street Lending Program Loan (“MSLP Loan”) was purchased by affiliates of Madryn Asset Management, LP (“Madryn”) for an undisclosed amount from the City National Bank of Florida (the “MSLP Loan Purchase”). Following close of the MSLP Loan Purchase, Venus Concept and Madryn entered into a Loan and Security Agreement (“Madryn Loan Agreement”), dated April 23, 2024, pursuant to which Madryn provided an aggregate principal amount of up to
$5.0 million in debt financing to the Company to support near-term liquidity requirements. A principal amount of$2.0 million net of transaction fees, was drawn by the Company at the close of the transaction.
Management Commentary:
“First quarter revenue results exceeded the expectations we outlined on our fourth quarter report,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “Aesthetic capital equipment sales continue to be challenged by macroeconomic headwinds and our revenue results outside the U.S. continue to be impacted by the strategic initiatives we initiated last year. Importantly, our efforts to reposition the business and transition the Company to higher quality cash revenues, exiting unprofitable direct operations in international markets and other restructuring activities, are proving effective. We are enhancing our cash flow profile and accelerating the path to long-term, sustainable, profitability and growth.”
Mr. De Silva continued: “We recently announced the completion of the first phase of our restructuring efforts with Madryn’s purchase of our outstanding senior debt facility and extension of bridge financing. We appreciate Madryn’s ongoing support of the Company as we work towards cash flow breakeven and sustainable profitability. As the Company continues implementing its turnaround plans, debt restructuring and financing remain important near-term priorities to catalyze our growth plans. We look forward to sharing updates as we execute against these initiatives.”
First Quarter of 2024 Revenue by Region and by Product Type:
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| (dollars in thousands) | ||||||||
| Revenues by region: | ||||||||
| United States | $ | 9,080 | $ | 10,741 | ||||
| International | 8,399 | 9,790 | ||||||
| Total revenue | $ | 17,479 | $ | 20,531 | ||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| (dollars in thousands) | ||||||||
| Revenues by product: | ||||||||
| Subscription—Systems | $ | 3,531 | $ | 5,761 | ||||
| Products—Systems | 10,535 | 11,065 | ||||||
| Products—Other (1) | 2,557 | 2,947 | ||||||
| Services | 856 | 758 | ||||||
| Total revenue | $ | 17,479 | $ | 20,531 | ||||
| (1) Products-Other include ARTAS procedure kits, Viva tips, Glide and other consumables. | ||||||||
First Quarter 2024 Financial Results:
| Three Months Ended March 31, | ||||||||||||||||||||||||
| 2024 | 2023 | Change | ||||||||||||||||||||||
| (in thousands, except percentages) | $ | % of Total | $ | % of Total | $ | % | ||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||
| Subscription—Systems | $ | 3,531 | 20.2 | $ | 5,761 | 28.1 | $ | (2,230 | ) | (38.7 | ) | |||||||||||||
| Products—Systems | 10,535 | 60.3 | 11,065 | 53.9 | (530 | ) | (4.8 | ) | ||||||||||||||||
| Products—Other | 2,557 | 14.6 | 2,947 | 14.3 | (390 | ) | (13.2 | ) | ||||||||||||||||
| Services | 856 | 4.9 | 758 | 3.7 | 98 | 12.9 | ||||||||||||||||||
| Total | $ | 17,479 | 100.0 | $ | 20,531 | 100.0 | $ | (3,052 | ) | (14.9 | ) | |||||||||||||
Total revenue for the first quarter of 2024 decreased
Gross profit for the first quarter of 2024 decreased
Operating expenses for the first quarter of 2024 decreased
Operating loss for the first quarter of 2024 was
Net loss attributable to stockholders for the first quarter of 2024 was
As of March 31, 2024, the Company had cash and cash equivalents of
Fiscal Year 2024 Financial Outlook:
Given the Company’s active dialogue with existing lenders and investors and the ongoing evaluation of strategic alternatives with various interested parties to maximize shareholder value, the Company is not providing full year 2024 financial guidance at this time. The Company expects total revenue for the three months ending June 30, 2024 of at least
Conference Call Details:
Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2024 to discuss the results of the quarter with a question-and-answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13745887. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13745887. The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 10 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors, including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, but are not limited to, statements about our financial performance and metrics; the growth in demand for our systems and other products; the efficacy of the Venus Versa Pro; the contribution of the Venus Versa Pro to our revenue; the efficacy of the restructuring plan; the identification and efficacy of strategic alternatives to maximize shareholder value; the reduction in our cash burn; and the continued implementation of turnaround plans, including debt restructurings and financings. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
| Venus Concept Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands of U.S. dollars, except share and per share data) | ||||||||
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 5,087 | $ | 5,396 | ||||
| Accounts receivable, net of allowance of | 27,168 | 29,151 | ||||||
| Inventories | 20,978 | 23,072 | ||||||
| Prepaid expenses | 1,034 | 1,298 | ||||||
| Advances to suppliers | 4,926 | 5,604 | ||||||
| Other current assets | 1,508 | 1,925 | ||||||
| Total current assets | 60,701 | 66,446 | ||||||
| LONG-TERM ASSETS: | ||||||||
| Long-term receivables, net | 9,906 | 11,318 | ||||||
| Deferred tax assets | 1,148 | 1,032 | ||||||
| Severance pay funds | 429 | 573 | ||||||
| Property and equipment, net | 1,229 | 1,322 | ||||||
| Operating right-of-use assets, net | 4,081 | 4,517 | ||||||
| Intangible assets | 7,582 | 8,446 | ||||||
| Total long-term assets | 24,375 | 27,208 | ||||||
| TOTAL ASSETS | $ | 85,076 | $ | 93,654 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Trade payables | $ | 7,787 | $ | 9,038 | ||||
| Accrued expenses and other current liabilities | 12,133 | 12,437 | ||||||
| Current portion of long-term debt | 4,154 | 4,155 | ||||||
| Income taxes payable | 479 | 366 | ||||||
| Unearned interest income | 1,444 | 1,468 | ||||||
| Warranty accrual | 1,107 | 1,029 | ||||||
| Deferred revenues | 926 | 1,076 | ||||||
| Operating lease liabilities | 1,418 | 1,590 | ||||||
| Total current liabilities | 29,448 | 31,159 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Long-term debt | 72,552 | 70,790 | ||||||
| Accrued severance pay | 467 | 634 | ||||||
| Deferred tax liabilities | 11 | 15 | ||||||
| Unearned interest revenue | 724 | 671 | ||||||
| Warranty accrual | 268 | 334 | ||||||
| Operating lease liabilities | 2,846 | 3,162 | ||||||
| Other long-term liabilities | 672 | 338 | ||||||
| Total long-term liabilities | 77,540 | 75,944 | ||||||
| TOTAL LIABILITIES | 106,988 | 107,103 | ||||||
| Commitments and Contingencies (Note 9) | ||||||||
| STOCKHOLDERS’ EQUITY (DEFICIT) (Note 15): | ||||||||
| Common Stock, | 30 | 30 | ||||||
| Additional paid-in capital | 249,180 | 247,854 | ||||||
| Accumulated deficit | (271,697 | ) | (261,903 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | (22,487 | ) | (14,019 | ) | ||||
| Non-controlling interests | 575 | 570 | ||||||
| (21,912 | ) | (13,449 | ) | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 85,076 | $ | 93,654 | ||||
| Venus Concept Inc. | ||||||||
| Condensed Consolidated Statements of Operations | ||||||||
| (In thousands of U.S. dollars, except per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | ||||||||
| Leases | $ | 3,593 | $ | 5,761 | ||||
| Products and services | 13,886 | 14,770 | ||||||
| 17,479 | 20,531 | |||||||
| Cost of goods sold: | ||||||||
| Leases | 1,477 | 1,747 | ||||||
| Products and services | 4,355 | 5,085 | ||||||
| 5,832 | 6,832 | |||||||
| Gross profit | 11,647 | 13,699 | ||||||
| Operating expenses: | ||||||||
| Selling and marketing | 7,374 | 8,032 | ||||||
| General and administrative | 10,248 | 11,185 | ||||||
| Research and development | 1,785 | 2,637 | ||||||
| Total operating expenses | 19,407 | 21,854 | ||||||
| Loss from operations | (7,760 | ) | (8,155 | ) | ||||
| Other expenses: | ||||||||
| Foreign exchange (gain) loss | 324 | (352 | ) | |||||
| Finance expenses | 1,668 | 1,508 | ||||||
| Loss on disposal of subsidiaries | — | 77 | ||||||
| Loss before income taxes | (9,752 | ) | (9,388 | ) | ||||
| Income tax expense | 37 | 235 | ||||||
| Net loss | $ | (9,789 | ) | $ | (9,623 | ) | ||
| Net loss attributable to stockholders of the Company | $ | (9,794 | ) | $ | (9,657 | ) | ||
| Net income attributable to non-controlling interest | $ | 5 | $ | 34 | ||||
| Net loss per share: | ||||||||
| Basic | $ | (1.68 | ) | $ | (1.84 | ) | ||
| Diluted | $ | (1.68 | ) | $ | (1.84 | ) | ||
| Weighted-average number of shares used in per share calculation: | ||||||||
| Basic | 5,829 | 5,237 | ||||||
| Diluted | 5,829 | 5,237 | ||||||
| Venus Concept Inc. | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (in thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (9,789 | ) | $ | (9,623 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 975 | 1,007 | ||||||
| Stock-based compensation | 339 | 481 | ||||||
| Provision for expected credit losses | 171 | 618 | ||||||
| Provision for inventory obsolescence | 372 | 343 | ||||||
| Finance expenses and accretion | 481 | 74 | ||||||
| Deferred tax recovery | (120 | ) | 149 | |||||
| Loss on disposal of property and equipment | 5 | 34 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable short-term and long-term | 3,226 | 1,654 | ||||||
| Inventories | 1,722 | 891 | ||||||
| Prepaid expenses | 264 | 69 | ||||||
| Advances to suppliers | 678 | 20 | ||||||
| Other current assets | 417 | 1,673 | ||||||
| Operating right-of-use assets, net | 437 | 423 | ||||||
| Other long-term assets | (1 | ) | (45 | ) | ||||
| Trade payables | (1,251 | ) | (522 | ) | ||||
| Accrued expenses and other current liabilities | (263 | ) | (2,570 | ) | ||||
| Current operating lease liabilities | (172 | ) | (119 | ) | ||||
| Severance pay funds | 144 | 43 | ||||||
| Unearned interest income | 29 | (360 | ) | |||||
| Long-term operating lease liabilities | (316 | ) | (289 | ) | ||||
| Other long-term liabilities | (226 | ) | 161 | |||||
| Net cash used in operating activities | (2,878 | ) | (5,888 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment | (25 | ) | (70 | ) | ||||
| Net cash used in investing activities | (25 | ) | (70 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock | 10 | 803 | ||||||
| 2024 Registered Direct Offering shares and warrants, net of costs of | 977 | — | ||||||
| 2024 Convertible Notes issued to EW, net of costs of | 1,607 | — | ||||||
| Net cash provided by financing activities | 2,594 | 803 | ||||||
| NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (309 | ) | (5,155 | ) | ||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period | 5,396 | 11,569 | ||||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period | $ | 5,087 | $ | 6,414 | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for income taxes | $ | 27 | $ | 12 | ||||
| Cash paid for interest | $ | 1,187 | $ | 1,433 | ||||
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange (gain) loss, financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.
We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a non-cash expense) and non-recurring items as explained below.
The following reconciliation of net (loss) income to Adjusted EBITDA for the periods presented:
| Venus Concept Inc. | ||||||||
| Reconciliation of Net loss to Non-GAAP Adjusted EBITDA | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Reconciliation of net loss to adjusted EBITDA | (in thousands) | |||||||
| Net loss | $ | (9,789 | ) | $ | (9,623 | ) | ||
| Foreign exchange (gain) loss | 324 | (352 | ) | |||||
| Loss on disposal of subsidiaries | — | 77 | ||||||
| Finance expenses | 1,668 | 1,508 | ||||||
| Income tax expense | 37 | 235 | ||||||
| Depreciation and amortization | 975 | 1,022 | ||||||
| Stock-based compensation expense | 339 | 481 | ||||||
| CEWS (1) | 418 | — | ||||||
| Other adjustments (2) | 910 | 917 | ||||||
| Adjusted EBITDA | $ | (5,118 | ) | $ | (5,735 | ) | ||
(1) In April 2022, the Canada Revenue Agency (“CRA”) initiated an audit of the Canada Emergency Wage Subsidy Claim (“CEWS”) that the Company filed between 2020-2021. The CRA has currently assessed a denial of CEWS claims made by the Company in 2020 and requesting repayment of
(2) For the three months ended March 31, 2024 and March 31, 2023 the other adjustments are represented by restructuring activities designed to improve the Company's operations and cost structure.
FAQ
What were Venus Concept's Q1 2024 revenues?
How much cash did Venus Concept use in operations in Q1 2024?
What recent approvals did Venus Concept receive?
What is Venus Concept's forecast for Q2 2024 revenue?
How did Venus Concept's operating expenses change in Q1 2024?
What was Venus Concept's gross profit and margin in Q1 2024?
How much debt financing did Venus Concept secure from Madryn Asset Management?
What was Venus Concept's net loss in Q1 2024?
